Brand strategy and rebranding

Novo Nordisk recognises that Ozempic has become a true cultural phenomenon and is therefore dropping the name Rybelsus in favour of the better-known brand.

The semaglutide franchise is changing up its branding as Novo Nordisk, seeing the cultural phenomenon that has become Ozempic, is retiring the Rybelsus name in favor of its better-known brand. Meet the “Ozempic pill,” a newly tweaked formulation of Novo’s Type 2 diabetes tablet Rybelsus, which is slightly smaller and uses a new coating and eschews its former badge. The Rybelsus brand won’t be carried forward but the tablets will continue under the iconic brand of Ozempic.

This changeup comes from two ways of thinking: simplicity in marketing and tapping into the success of the Ozempic brand. The Type 2 diabetes market is very complex, and there are a multitude of options. The GLP-1 class itself has grown significantly ever since the introduction of Ozempic. Since the approval of injectable Ozempic in 2018, use of these drugs has gone up 10x in the U.S., and the market for these drugs has also grown.

Novo Nordisk wants people to know they can receive Ozempic holistically: either in a pen form or now in a pill and really try to simplify things for the customer.